Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005581
Abstract: In patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC), atezolizumab therapy improves survival with manageable safety. The open-label, single-arm phase III/IV TAIL study (NCT03285763) evaluated atezolizumab monotherapy in patients with previously… read more here.
Keywords: treated advanced; non small; previously treated; small cell ... See more keywords
Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study
Sign Up to like & getrecommendations! Published in 2022 at "Disease Markers"
DOI: 10.1155/2022/4322404
Abstract: Background Apatinib is established to be the standard of care as third-line therapy for patients with previously treated advanced gastric cancer (GC). Programmed cell death protein 1 (PD-1) blockades also exhibited promising efficacy and safety… read more here.
Keywords: treated advanced; plus inhibitors; previously treated; apatinib plus ... See more keywords
Abstract CT269: A phase 2 study of olaparib in combination with pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination repair deficiency (HRD): KEYLYNK-007
Sign Up to like & getrecommendations! Published in 2020 at "Tumor Biology"
DOI: 10.1158/1538-7445.am2020-ct269
Abstract: Background: Treatment with the anti-PD-1 antibody pembrolizumab has improved clinical outcomes in multiple previously treated advanced solid tumors. The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib has shown antitumor activity as monotherapy in patients with previously… read more here.
Keywords: solid tumors; advanced solid; treated advanced; homologous recombination ... See more keywords
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
Sign Up to like & getrecommendations! Published in 2022 at "Liver Cancer"
DOI: 10.1159/000527175
Abstract: Introduction: Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab… read more here.
Keywords: hepatocellular carcinoma; treated advanced; previously treated; tislelizumab ... See more keywords
Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2017.03.104
Abstract: BACKGROUND The anti-PD-1/PD-L1 monoclonal antibody has showed promising results in various cancers via enhancing T cell functions. However, many questions remain in the role and safety in previously-treated, advanced non-small-cell lung cancer (NSCLC). Thus, we… read more here.
Keywords: chemotherapy; anti antibody; treated advanced; antibody ... See more keywords